Published in Breast on October 17, 2007
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat (2013) 1.10
Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res (2009) 1.09
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol (2010) 0.96
Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One (2011) 0.86
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat (2011) 0.85
Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens. Onco Targets Ther (2013) 0.78
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog (2009) 4.24
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev (2010) 2.35
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene (2003) 1.73
Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med (2012) 1.69
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol (2012) 1.55
Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther (2005) 1.50
Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer (2004) 1.46
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer (2011) 1.36
Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res (2004) 1.33
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res (2012) 1.27
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res (2007) 1.26
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res (2012) 1.26
Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep (2012) 1.17
Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res (2004) 1.12
STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer. Int J Clin Exp Pathol (2010) 1.07
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol (2005) 1.06
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat (2006) 1.02
Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. Psychooncology (2010) 1.01
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets (2011) 0.94
Clinical and biological significance of GSK-3β inactivation in breast cancer-an immunohistochemical study. Hum Pathol (2010) 0.93
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res (2013) 0.93
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat (2013) 0.91
Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. Am J Clin Oncol (2007) 0.87
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer (2002) 0.84
Clinically validated benchmarking of normalisation techniques for two-colour oligonucleotide spotted microarray slides. Appl Bioinformatics (2003) 0.83
Plakoglobin interacts with the transcription factor p53 and regulates the expression of 14-3-3σ. J Cell Sci (2013) 0.81
A machine learned classifier that uses gene expression data to accurately predict estrogen receptor status. PLoS One (2013) 0.79
Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins. Breast Cancer Res Treat (2009) 0.79
Evidence for copurification of micronuclei in sucrose density gradient-enriched plasma membranes from cell lines. Anal Biochem (2009) 0.77
Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification. J Proteomics (2013) 0.76
Unexpected immunohistochemical localization of deoxycytidine kinase. Clin Cancer Res (2006) 0.75
Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer. JAMA (2005) 0.75
The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials. J Pharm Pharm Sci (2017) 0.75
Fulvestrant: clinical application of an estrogen receptor downregulator. Clin Ther (2002) 0.75
Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer (2011) 0.75